Drug Interactions between dexchlorpheniramine / phenylephrine and hyaluronidase

GENERALLY AVOID: Hyaluronidase may enhance the absorption and dispersion of dopamine and/or other injectable alpha agonist drugs, resulting in cardiovascular effects such as increased blood pressure, increased vascular resistance and other alpha adrenergic-mediated adverse effects. Hyaluronidase is a dispersion agent, that can increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. There are no clinical data available for this interaction.

MANAGEMENT: The manufacturer of hyaluronidase recommends avoiding the use of hyaluronidase to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Some authorities consider this particular use of hyaluronidase as contraindicated. However, hyaluronidase used for other indications, may be administered to patients receiving dopamine and/or alpha agonist drugs. Consultation with product labeling and local or institutional guidelines may be appropriate for further recommendations.

Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.